ISSN: 2329-6631
Journal of Developing Drugs
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
 
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business
 

The Head of Janus: Exploiting Autophagy for Cancer Therapy

Donat Kögel*
Experimental Neurosurgery, Department of Neurosurgery, Frankfurt University, Germany
*Corresponding Author : Donat Koegel
Experimental Neurosurgery, Department of Neurosurgery
Goethe University Hospital, Frankfurt University, Germany
Tel: 49-69-6301-6940
Fax: 49-69-6301-5575 E-mail: koegel@em.uni-frankfurt.de
Received February 08, 2012; Accepted February 11, 2012; Published February 14, 2012
Citation: Kögel D (2012) The Head of Janus: Exploiting Autophagy for Cancer Therapy. J Develop Drugs 1:e109. doi: 10.4172/2329-6631.1000e109
Copyright: © 2012 Kögel D. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Developing Drugs

Macroautophagy (hereafter referred to as autophagy) is a complex, multi-step process normally involved in regulated turnover of longlived proteins and damaged organelles. Autophagy is a form of cellular self digestion in which cellular constituents are engulfed in doublemembrane containing autophagosomes. Their vesicular content is subsequently digested by lysosomal proteases after fusion of autophagosomes with lysosomes. In recent years, elucidation of the physiological and pathophysiological aspects of autophagy and the identification of key components of the autophagy interacting network has generated a tremendous interest in the concept of exploiting autophagy for cancer therapy [1-4].
What is the common rationale of targeting autophagy for cancer therapy? The net effects of autophagy on cell death/cell survival decisions are highly dependent of the cellular context and hence autophagy may have dual, opposing roles [5]. It is now widely accepted that autophagy primarily constitutes a quality control mechanism and a prosurvival stress response, e.g. under conditions of nutrient deprivation, organelle damage, oxidative stress or after DNA damage [6]. In line with this hypothesis, there are numerous examples and experimental paradigms where pharmacological inhibition or genetic ablation of pro-survival autophagy can sensitize cancer cells to various types of therapy [7,8]. On the other hand, there is also evidence supporting the notion that enforced over activation of autophagy can lead to “autophagic cell death” (type II cell death), i.e. massive cellular self digestion via the autophagosomal-lysosomal pathway beyond the point allowing cell survival. This could be especially relevant in apoptosis-resistant cells such as gliobastoma cells, where autophagy may act as a backup cell death mechanism executing a non-apoptotic, alternative death program [9,10].
However, this is a controversial, hotly debated issue [11,12] and the very existence of autophagic cell death has been challenged recently [13]. Indeed, in many paradigms of cell death associated with induction of autophagy, autophagy may just act as a bystander without a direct role in the death process. In line with this notion, many of the past studies on “autophagic cell death” did not really investigate the pro-death function of autophagy and therefore do not fulfil the current, more stringent criteria that recently were suggested to be applied for autophagy-dependent cell death [5,11].
Despite this ongoing controversy regarding the pro-death role of autophagy, there are a number of experimental studies suggesting that pro-autophagic drugs may elicit an autophagy-dependent cell death in certain cases [8]. In addition to these findings on drug-induced autophagic cell death in mammalian cells, there is also considerable evidence for autophagy-dependent developmental cell death in Drosophila [14,15]. Therefore, the issue of autophagy as a cell death mechanism in general and the ensuing therapeutic consequences for cancer therapy warrant further examination in order to determine whether activation of autophagy may indeed have significance for therapy, especially in apoptosis-refractory tumors.
References


Select your language of interest to view the total content in your interested language
 
Share This Article
   
 
   
 
Relevant Topics
Disc Adverse Drug Reactions
Disc Antigen – Antibody Reaction
Disc Anvisa Drug Safety Regulations
Disc Biochemical Metabolism
Disc Clinical Pharmacoepidemiological Trails
Disc Cytochrome 450 Drug Metabolism
Disc Cytotoxicity
Disc Detoxification
Disc Drug Delivery
Disc Drug Delivery Systems
Disc Drug Delivery using Nanotechnology
Disc Drug Designing
Disc Drug Development
Disc Drug Discovery
Disc Drug Interaction
Disc Drug Interactions
Disc Drug Metabolism
Disc Drug Safety Databases
Disc Drug Safety Information Maintenance
Disc Drug Safety Regulations
Disc Drug Therapy
Disc Drug Toxicology
Disc Drug drug interaction
Disc Drug food interaction
Disc Drugs metabolised by CYP2D6
Disc Europeon Drug Safety Regulations
Disc Expert Opinions on Drug Safety
Disc Fragment Based Drug Design
Disc Heat Shock Proteins
Disc Hepatic Metabolism of Drugs
Disc In Silico Methods
Disc Liver Drug Metabolism
Disc Medication Errors
Disc Molecular Modeling
Disc Nanomedicals
Disc Peptidomimetic
Disc Pharmaceutical Industry
Disc Pharmaceutical Toxicology
Disc Pharmacoepidemiological Studies
Disc Pharmacotherapy
Disc Phase I Drug Metabolism
Disc Phase II Drug Metabolism
Disc Pre-Clinical Drug Development
Disc Protease Substrate/Inhibitor
Disc Receptor Agonist/ Antagonist
Disc Reviews on Drug Safety
Disc Structure Based Drug Design
Disc UK Drug Safety Regulations
Disc US Drug Safety Regulations
Disc screening and Drug Design
 
Recommended Journals
Disc Pharmaceutical Sciences & Emerging Drugs Journal
Disc Pharmaceutics & Drug Delivery Research Journal
Disc Drug Metabolism & Toxicology Journal
Disc Drug Development & Research International Journal
Disc Drug Designing: Open Access
Disc Drug Designing: Open Access
Disc Advances in Pharmacoepidemiology & Drug Safety
  View More»
 
Recommended Conferences
Disc Asia-Pacific Drug Formulation
July 11-13, 2016 Kuala Lumpur, Malaysia
Disc Conference on Nanomedicine
July 25-27, 2016 Bangkok, Thailand
Disc Conference on GMP GCP Quality Control
August 15-16, 2016 Toronto, Ontario, Canada
Disc Global Pharma Conference
August 22-24, 2016 New Orleans, Louisiana, USA
Disc Generic Drug Market
October 31 – November 2, 2016 Valencia, Spain
Disc Conference on Parenterals
November 07-08, 2016 Istanbul, Turkey
Disc Conference on Pharma Marketing
Nov 10-12, 2016 Alicante, Spain
Disc Polymer Chemistry Conference
November 14-16, 2016 Atlanta, USA
 
Article Tools
Disc Export citation
Disc Share/Blog this article
 
Article usage
  Total views: 11135
  [From(publication date):
February-2012 - May 25, 2016]
  Breakdown by view type
  HTML page views : 7408
  PDF downloads :3727
 
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

 
OMICS International Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
 
 
OMICS International Conferences 2016-17
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings
 
 

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsinc.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsinc.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsinc.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsinc.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsinc.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsinc.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsinc.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsinc.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsinc.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsinc.com

1-702-714-7001Extn: 9039

Materials Science Journals

Rachle Green

materialsci@omicsinc.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsinc.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsinc.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsinc.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsinc.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsinc.com

1-702-714-7001 Extn: 9042

 
© 2008-2016 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version